317321-89-4
Chemical Structure
BAS00602705
- CAS No.: 317321-89-4
- Formula:C25H22BrN3O3
- Molecular Weight:492.36
InChIKey: PODWVIXNCKDPAZ-UHFFFAOYSA-N
SMILES: O=C(NC(CC1=CNC2=C1C=CC=C2)C(NC3=CC=C(C=C3)Br)=O)OCC4=CC=CC=C4
Biological Activity: BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC)[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BAS00602705 | 98.96% | BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
